Overview

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
Phase:
Phase 2
Details
Lead Sponsor:
Vedanta Biosciences, Inc.
Treatments:
Vancomycin